Core Viewpoint - The announcement details the completion of the 2025 restricted stock incentive plan by Jiangsu Lanfeng Biological Chemical Co., Ltd, including the number of shares granted, the recipients, and the conditions for vesting and performance assessment [1][19]. Group 1: Stock Grant Details - The number of restricted shares granted is 20.03 million, accounting for 5.63% of the company's total shares before the grant [1][7]. - The grant date for the restricted shares is November 24, 2025, with the shares set to be listed on December 8, 2025 [6][16]. - The grant price for the restricted shares is set at 2.64 yuan per share [7]. Group 2: Recipients and Approval Process - A total of 71 individuals are designated as recipients of the restricted shares, including senior management, middle management, and key employees [2][7]. - The decision-making process involved multiple board meetings and approvals, with legal opinions provided by Beijing Wanshang Tianqin Law Firm [3][5]. Group 3: Vesting Conditions - The vesting period for the restricted shares is set at 12 months and 24 months from the date of grant, during which the shares cannot be transferred or used as collateral [8][9]. - Performance assessment for the vesting of shares will be based on company-level and individual-level criteria over the years 2025 and 2026 [10][12]. Group 4: Financial Impact - The total number of shares after the grant will increase from 355.56 million to 375.59 million, affecting the shareholding structure of major shareholders [17][19]. - The incentive plan is expected to raise approximately 52.88 million yuan, which will be used to supplement working capital [15][17]. Group 5: Compliance and Reporting - The company has confirmed that there were no stock trading activities by participating directors and senior management in the six months prior to the grant [18]. - The company will continue to monitor shareholder equity changes and comply with relevant disclosure obligations [19].

天眼查App显示，近日，石家庄麦朵生物科技有限公司成立，法定代表人为刘建龙，注册资本5万人民 币，经营范围为一般项目：技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广;生物化 工产品技术研发;化工产品生产（不含许可类化工产品）;化工产品销售（不含许可类化工产品）;饲料原 料销售;畜牧渔业饲料销售;生物饲料研发;饲料添加剂销售;肥料销售;生物有机肥料研发;化肥销售;农副产 品销售;日用化学产品销售;专用化学产品销售（不含危险化学品）;初级农产品收购;生物基材料销售;机 械设备销售;木材加工;建筑材料销售;五金产品零售;货物进出口（除依法须经批准的项目外，凭营业执 照依法自主开展经营活动）许可项目：饲料生产;饲料添加剂生产;肥料生产（依法须经批准的项目，经 相关部门批准后方可开展经营活动，具体经营项目以批准文件或许可证件为准）。 ...

Core Viewpoint - Harbin Air Conditioning (哈空调) is attempting to divest its underperforming subsidiary, Harbin Fushanchuan Biotechnology Development Co., Ltd. (富山川), to streamline operations amid financial pressures and a need for transformation [1][2] Group 1: Asset Divestiture - The company plans to publicly transfer 40% of its stake in Fushanchuan at a minimum price of 3.8126 million yuan, based on an assessed value [2][3] - Fushanchuan has ceased operations and is currently in a "dormant state," with a reported net loss of 16.0963 million yuan for 2024, which is 218.83% of Harbin Air Conditioning's previous year's net profit [2][3] - The valuation of Fushanchuan shows a 7.69% increase from its book value, with total equity assessed at 9.5314 million yuan [2] Group 2: Financial Challenges - Harbin Air Conditioning's revenue for the first three quarters of 2025 was 827 million yuan, a year-on-year decrease of 12.19%, with a net loss of 23.8215 million yuan [3] - Fushanchuan has been listed as a dishonest executor, with its bank accounts frozen due to legal disputes, and it is involved in multiple contract disputes that have led to additional financial liabilities [4] - The company has an outstanding unfulfilled capital contribution of 15.4718 million yuan related to its investment in Fushanchuan, which poses a financial risk [4][5] Group 3: Internal Financial Obligations - Fushanchuan owes Harbin Air Conditioning approximately 19.7955 million yuan in various internal debts, with no clear repayment plan provided [5] - The other shareholders of Fushanchuan have waived their right of first refusal on the share transfer, necessitating Harbin Air Conditioning to seek external buyers [5] - The company has acknowledged the uncertainty surrounding the success of the transaction and the final terms of the sale [5]

本报讯(记者袁传玺)天眼查工商信息显示，近日，哈尔滨裕诚生物技术有限公司成立，注册资本2000万 元，经营范围含生物化工产品技术研发、发酵过程优化技术研发、化工产品生产、互联网销售等。股东 信息显示，该公司由哈三联（002900）全资持股。 ...

天眼查App显示，近日，山东赛茵特生物科技有限公司成立，法定代表人为丁培杰，注册资本8000万人 民币，经营范围为一般项目：生物化工产品技术研发；生物农药技术研发；化工产品销售（不含许可类 化工产品）；技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广；技术进出口；货物进 出口。（除依法须经批准的项目外，凭营业执照依法自主开展经营活动）许可项目：农药批发；农药零 售。（依法须经批准的项目，经相关部门批准后方可开展经营活动，具体经营项目以相关部门批准文件 或许可证件为准）。 ...

天眼查App显示，近日，江西玲隆生物科技有限公司成立，法定代表人为韩文，注册资本3万人民币， 经营范围为一般项目：生物化工产品技术研发，新材料技术研发，新材料技术推广服务，技术服务、技 术开发、技术咨询、技术交流、技术转让、技术推广，非食用植物油销售，传统香料制品经营，日用化 学产品销售，日用杂品销售，化妆品零售，化妆品批发，消毒剂销售（不含危险化学品），日用百货销 售，日用品销售，日用品批发，食品添加剂销售，专用化学产品销售（不含危险化学品），农副产品销 售，初级农产品收购，中草药收购，树木种植经营，个人卫生用品销售，香料作物种植，饲料添加剂销 售，化工产品销售（不含许可类化工产品），货物进出口（除依法须经批准的项目外，凭营业执照依法 自主开展经营活动）。 ...

Core Points - The event is a specialized job fair for university students in Zhengzhou, organized by the Jinshui District Human Resources and Social Security Bureau and the Dongfeng Road Street Office on November 22, 2023 [1] - The job fair targets various urgent employment groups, including young talents, high-level talents, recent graduates, and unemployed youth [1] - Over 11,000 job positions will be available across multiple industries, including finance, biochemistry, environmental technology, education, manufacturing, and more [1] Industry Summary - The participating companies span diverse sectors such as finance, biochemistry, environmental technology, education, mechanical manufacturing, precision electronics, digital intelligence, tourism, cultural media, law, building materials, and food [1] - Job positions will cover a wide range of professional categories, focusing on software development, management trainees, new media operations, e-commerce, foreign trade, technical research and development, project management, administration, design, finance, engineering, broadcasting, law, marketing, and internships [1] Event Details - The job fair will take place on November 22, 2023, from 9:00 AM to 12:00 PM at the first floor hall of Zhihui City [1] - The venue is accessible via the subway line 7, with specific directions provided for attendees [1] - Additional features at the event include a recruitment area, a company display area, and mobile options for resume submission [1]

天眼查App显示，近日，江西博纳生物科技有限公司成立，法定代表人为陈良明，注册资本2000万人民 币，经营范围为一般项目：生物化工产品技术研发，货物进出口，日用化学产品制造，日用化学产品销 售，专用化学产品制造（不含危险化学品），专用化学产品销售（不含危险化学品），初级农产品收 购，技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广（除依法须经批准的项目外，凭 营业执照依法自主开展经营活动）。 ...

Core Viewpoint - A new company, Xiangguan (Liaocheng) Biotechnology Co., Ltd., has been established with a registered capital of 300,000 RMB, focusing on various biotechnology and chemical product developments and sales [1] Company Overview - The legal representative of the company is Fu Yanhui [1] - The registered capital of the company is 300,000 RMB [1] Business Scope - The company engages in a wide range of activities including: - Research and development of biochemistry products [1] - Sales of sanitary insecticides and disinfectants (excluding hazardous chemicals) [1] - Manufacturing of daily chemical products and traditional fragrance products [1] - Retail and wholesale of cosmetics [1] - Research and development of biological organic fertilizers and biopesticides [1] - Sales of various agricultural products and feed additives [1] - Technology services including consulting, development, and transfer [1] - Research and development of marine biological active substances [1] - Sales of first and second-class medical devices [1] - Sales of health food and fermented feed [1]

Core Viewpoint - The FDCA (Furandicarboxylic Acid) market is experiencing significant growth due to its potential to replace petroleum-based products, particularly in the production of PEF (Polyethylene Furanoate), which offers superior barrier properties compared to PET (Polyethylene Terephthalate) [3][14]. Group 1: Product Definition and Market Overview - FDCA is a key raw material for high-performance bio-based polymers, including PEF, and is derived from 5-HMF [2]. - The global FDCA market is projected to grow from approximately $1.38 million in 2022 to $77.79 million by 2031, with a compound annual growth rate (CAGR) of 30.1% from 2025 to 2031 [5]. - The commercialization of FDCA began in 2022, following increased research and development efforts since 2018 [3]. Group 2: Regional Market Dynamics - The European and Chinese markets currently dominate the FDCA market, with Europe expected to account for 32.8% and China for 66.0% of the global market value by 2024 [8]. - The production of 99.9% pure FDCA is the mainstream product, projected to represent 95.4% of global output by 2024 [8]. Group 3: Industry Players and Competition - Major players in the FDCA market include Avantium, Novamont, Stora Enso, Origin Materials, and others, with the top five companies expected to hold over 90% market share by 2024 [9]. - The competition in the industry is anticipated to intensify, particularly in the Chinese market [9]. Group 4: Applications and Future Trends - PEF is the primary application for FDCA, expected to account for approximately 92.1% of its usage in 2024 [8]. - The potential for FDCA to be used in various applications, including engineering plastics, polyamides, and polyurethanes, is significant, driven by its strong barrier properties [14]. Group 5: Policy and Regulatory Environment - The Chinese government is increasingly supportive of bio-based materials, including FDCA, as part of its environmental policies aimed at reducing carbon emissions [16]. - FDCA is classified as an "allowed" product under the 2024 Industrial Structure Adjustment Guidance Catalog, indicating a favorable regulatory environment for its development [16].